{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:40:18Z","timestamp":1760150418638,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jpainsymman.2021.02.007","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T06:55:44Z","timestamp":1613372144000},"page":"e225-e231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-Term Daily Administration of Aprepitant for the Management of Intractable Nausea and Vomiting in Children With Life-Limiting Conditions: A Case Series"],"prefix":"10.1016","volume":"62","author":[{"given":"Bhumik","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Downie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Bayliss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myra","family":"Bluebond-Langner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jpainsymman.2021.02.007_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000104540","article-title":"Management of non-pain symptoms in paediatric palliative care","volume":"16","author":"Friedrichsdorf","year":"2007","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0002","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0885-3924(03)00202-1","article-title":"The symptoms of dying children","volume":"26","author":"Drake","year":"2003","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0003","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1056\/NEJM200006293422615","article-title":"Symptoms and suffering at the end of life in children with cancer","volume":"342","author":"Goldman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0004","first-page":"103","article-title":"An overview of nausea\/vomiting in palliative medicine","volume":"1","author":"Smith","year":"2012","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/children5040053","article-title":"Children's experiences of symptoms: narratives through words and images","volume":"5","author":"Sourkes","year":"2018","journal-title":"Children"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0006","series-title":"Textbook of interdisciplinary paediatric palliative care","first-page":"311","article-title":"Gastrointestinal symptoms","author":"Friedrichsdorf","year":"2011"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0007","series-title":"Oxford textbook of palliative care for children","first-page":"271","article-title":"Management of the gastrointestinal tract in paediatric palliative medicine","author":"Miller","year":"2012"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/1756283X15618131","article-title":"Nausea: a review of pathophysiology and therapeutic","volume":"9","author":"Singh","year":"2016","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0009","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.neuron.2019.01.034","article-title":"Substance P and inflammatory pain: getting it wrong and right simultaneously","volume":"101","author":"Navratilova","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0010","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/32776","article-title":"Pharmacology: substance P equals pain substance?","volume":"392","author":"Iversen","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0011","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2340\/00015555-2780","article-title":"Role of substance P and its receptor neurokinin 1 in chronic prurigo: a randomized, proof of concept, controlled trial with topical aprepitant","volume":"98","author":"Ohanyan","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0012","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.jpain.2017.12.063","article-title":"Central amygdala neurons modulate pruritic processing","volume":"19","author":"Samineni","year":"2018","journal-title":"J Pain"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0013","first-page":"1","article-title":"Aprepitant for the treatment of chronic refractory pruritis","author":"He","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0014","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1126\/science.281.5383.1640","article-title":"Distinct mechanism for anti-depressant activity by blockade of central substance P receptors","volume":"281","author":"Kramer","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0015","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1634\/theoncologist.2014-0229","article-title":"Aprepitant and fosaprepitant: a 10-year review of efficacy and safety","volume":"20","author":"Aapro","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0016","first-page":"1","article-title":"Use of aprepitant to prevent nausea and vomiting in children","volume":"21","author":"Buck","year":"2015","journal-title":"Paediatr Pharmacother"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0017","first-page":"127","article-title":"Aprepitant and fosaprepitant use in children and adolescents at an academic medical center","volume":"19","author":"Shillingburg","year":"2014","journal-title":"J Paediatr Pharm Ther"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/0019-509X.31164","article-title":"Aprepitant: a substance P antagonist for chemotherapy induced nausea and vomiting","volume":"44","author":"Manikandan","year":"2007","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0019","unstructured":"Medicines.org.uk. EMEND 125 mg powder for oral suspension-summary of product characteristics (SmPC)-(eMC). Electronic medicines compendium. [Online] 2019. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/7385\/smpc. Accessed March 17, 2021."},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0020","first-page":"871","article-title":"Comparison between 5-day aprepitant and single dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy","author":"Ando","year":"2016","journal-title":"Supportive Care Cancer"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0021","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/s41409-018-0231-4","article-title":"Long-term aprepitant for nausea and vomiting associated with gastroparesis in haematopoietic stem cell transplantation","volume":"53","author":"Jacobse","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0022","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-2228","article-title":"Disparities in inpatient intensity of end-of-life care for complex chronic conditions","volume":"143","author":"Johnston","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0023","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7748\/ncyp.30.2.8.s7","article-title":"Why is 24\/7 children's community palliative care still not widely available?","volume":"30","author":"Sadler","year":"2018","journal-title":"Nurs Child Young People"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0024","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jpainsymman.2019.02.015","article-title":"Patient controlled analgesia for children with life-limiting conditions in the community: results of a prospective observational study","volume":"57","author":"Henderson","year":"2019","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0025","doi-asserted-by":"crossref","first-page":"4790810","DOI":"10.1155\/2017\/4790810","article-title":"Aprepitant for the treatment of chronic refractory pruritis","volume":"2017","author":"He","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0026","doi-asserted-by":"crossref","first-page":"71","DOI":"10.23937\/2378-3419\/3\/6\/1071","article-title":"Prolonged use of aprepitant in metastatic breast cancer and a reduction in CA153 tumour marker levels","volume":"3","author":"Lee","year":"2016","journal-title":"Int J Cancer Clin Res"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0027","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/apt.12822","article-title":"Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome","volume":"40","author":"Cristofori","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.gastro.2017.08.033","article-title":"Aprepitant has mixed effects on nausea and reduces other symptoms in patients with gastroparesis and related disorders","volume":"154","author":"Pasricha","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0029","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/bcp.13322","article-title":"Aprepitant and fosaprepitant drug interactions: a systematic review","volume":"83","author":"Patel","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0030","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/1078155216631408","article-title":"Drug interactions with aprepitant or fosaprepitant: review of the literature and implications for clinical practice","volume":"23","author":"Dushenkov","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0031","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fneur.2017.00304","article-title":"The role of substance P in secondary pathophysiology after traumatic brain injury","volume":"8","author":"Vink","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0032","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1177\/1367493518807312","article-title":"Documentation of breakthrough pain in narrative clinical records of children with life-limiting conditions: feasibility of retrospective review","volume":"23","author":"Oostendorp","year":"2018","journal-title":"J Child Health Care"},{"key":"10.1016\/j.jpainsymman.2021.02.007_bib0033","doi-asserted-by":"crossref","first-page":"f2304","DOI":"10.1136\/bmj.f2304","article-title":"Influence of trial sample size on treatment effect estimates: meta-epidemiological study","volume":"346","author":"Dechartes","year":"2013","journal-title":"BMJ"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088539242100169X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088539242100169X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:31:44Z","timestamp":1760131904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088539242100169X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S088539242100169X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2021.02.007","relation":{},"ISSN":["0885-3924"],"issn-type":[{"type":"print","value":"0885-3924"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Daily Administration of Aprepitant for the Management of Intractable Nausea and Vomiting in Children With Life-Limiting Conditions: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2021.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine.","name":"copyright","label":"Copyright"}]}}